Antibody Discovery Demands More Than Throughput.
Most antibody discovery campaigns do not get a clear understanding of molecular behavior until late in the process, after clones are expressed and validated.
A unified approach is needed to intelligently pre-select antibodies, without limiting diversity, to prevent wasted efforts or loss of valuable hits.
Protein-first Pre-Selection of Antibodies.
Sequence functional antibody proteins from the immunoserum
Our REpAb® polyclonal antibody sequencing technology uses mass spectrometry and AI to derive the sequences of antigen specific mAbs from a complex mixture. REpAb® can be used on its own, or in combination with B cell sequencing, phage display and predictive AI techniques:
- More information – directly about the mAb phenotype
- Selection – earlier in the discovery process
- Cheaper / faster – reduce cost of expression and assays
Pre-select without unintentional limits to diversity
Access the whole diversity of 1018 mAbs produced in vivo, and use REpAb® to pre-select for:
With REpAb®, phenotypic selection happens prior to sequencing, prior to expressing and testing recombinants. Avoid unintentional limits to diversity caused by library or primer design, B cell death, or equipment capacity.
Antibody Discovery Platform Technologies.
Antibody Discovery Workflow.
Use the complete REpAb® Antibody Discovery Pipeline to go from antigen to final antibody candidates in as little as 12 weeks. REpAb® can start with just a pAb (de novo sequencing via mass spectrometry), or combining de novo sequencing with B cell repertoire sequencing (de novo + NGS).
Or, bolt-on REpAb® to your existing antibody discovery pipeline, to get proteomics pre-selection without increasing cycle time. Pre-selection saves recombinant expression and validation costs, and improves success rate 10X.
Antibody Discovery Service Success Stories.
“Rapid Novor was tasked with finding highly specific, high affinity antibodies against an important target- and they delivered powerful antibodies fit-for-purpose. Such antibodies are not easily obtained yet the Rapid Novor approach proved immediately successful, despite our time-constrained and stringent demands.”
